Real World Evidence Solution Market is expected to rise at a CAGR of 8.07% by 2032, estimates DelveInsight

The global real-world evidence (RWE) solutions market was valued at USD 2,832.33 million in 2024 and is projected to grow at a CAGR of 8.07% between 2025 and 2032, reaching USD 5,240.07 million by 2032. Market growth is primarily driven by the rising prevalence of chronic diseases and the increasing reliance on real-world data to understand their impact. Advancements in technologies such as big data analytics, artificial intelligence, and machine learning are enabling the efficient collection, processing, and analysis of large datasets. Moreover, RWE solutions are increasingly being adopted by pharmaceutical and biotechnology companies to optimize drug development, support regulatory submissions, facilitate market access, and monitor post-market drug performance. Collectively, these factors are fueling the expansion of the real-world evidence solutions market over the forecast period.

DelveInsight's Real World Evidence Solution Market Insights report provides the current and forecast market analysis, individual leading Real World Evidence Solution companies' market shares, challenges, Real World Evidence Solution market drivers, barriers, and trends, and key Real World Evidence Solution companies in the market.

Request for a sample page report @ https://www.delveinsight.com/report-store/real-world-evidence-solution-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Real World Evidence Solution Market Report
The Real World Evidence Solution market is projected to grow at a moderate CAGR from 2025 to 2032.
As per DelveInsight estimates, North America is anticipated to dominate the global Real World Evidence Solution market during the forecast period.
Notable Real World Evidence Solution companies such as IQVIA Inc., Optum, Inc., Flatiron Health, Oracle, Parexel International (MA) Corporation, Aetion, Inc., Tempus, Syapse, Inc., IBM, PerkinElmer Inc., Syneos Health, TriNetX, Evidera, Clinerion, Cegedim Health Data, and several others are currently operating in the Real World Evidence Solution market.
In April 2024, Flatiron Health, a healthtech firm specializing in leveraging real-world data to enhance cancer care, extended its partnership with the National Comprehensive Cancer Network® (NCCN®). Originally established in 2014, this collaboration focuses on maintaining the NCCN Quality & Outcomes Database, a cloud-based platform compiling data from NCCN member institutions.
In September 2023, Accen ture assisted Mount Sinai Health System in migrating its Epic EMR system to Microsoft Azure, representing the largest deployment of Epic on Azure to date. This transformation, initiated in 2022 in partnership with Avanade and Microsoft, aims to drive innovation and improve healthcare delivery.
In August 2023, Thermo Fisher Scientific Inc. finalized its acquisition of CorEvitas, LLC, a leading provider of regulatory-grade real-world evidence for medical treatments, from Audax Private Equity for $912.5 million in cash. The deal had been initially announced in July 2023.

To read more about the latest highlights related to the Real World Evidence Solution market, get a snapshot of the key highlights entailed in the Global Real World Evidence Solution Market Report https://www.delveinsight.com/sample-request/real-world-evidence-solution-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Real World Evidence Solution Overview

Real-world evidence (RWE) solutions harness data collected outside of traditional clinical trials-such as electronic health records, insurance claims, patient registries, and wearable devices-to generate insights into treatment effectiveness, safety, and patient outcomes across diverse populations. These solutions play a crucial role in guiding healthcare decisions, supporting regulatory approvals, optimizing clinical trial designs, and improving patient-centered care.

The market is driven by the rising prevalence of chronic diseases, the growing complexity of treatment pathways, and the increasing adoption of advanced technologies like artificial intelligence, machine learning, and big data analytics to process and analyze large volumes of healthcare data efficiently. Strategic collaborations, acquisitions, and partnerships among key players further enhance the availability and quality of RWE, accelerating innovation in drug development, post-market monitoring, and value-based care.

As healthcare systems globally focus on improving outcomes, reducing costs, and personalizing treatments, RWE solutions are becoming essential tools for stakeholders across the pharmaceutical, biotech, and clinical research sectors.

Real World Evidence Solution Market Insights

North America is projected to hold the largest share of the real-world evidence (RWE) solutions market in 2024 among all regions. This dominance is driven by the rising number of clinical trials spurred by the increasing prevalence of chronic diseases, alongside technological advancements such as artificial intelligence, machine learning, and sophisticated data analytics that enhance the processing and interpretation of large datasets, yielding key insights into treatment effectiveness and patient outcomes. Additionally, the presence of major pharmaceutical and biotechnology companies, coupled with ongoing research and development in drug discovery and development, further supports the growth of the RWE solutions market in the region.

According to the International Agency for Research on Cancer (2024), North America recorded approximately 2.67 million new cancer cases in 2022, with projections estimating an increase to 3.83 million by 2045. In Canada, around 292,000 new cancer cases were reported in 2022, expected to reach 449,000 by 2045. The rising cancer burden underscores the critical need for robust RWE solutions. These solutions provide valuable insights into treatment efficacy, support regulatory approvals, optimize healthcare resource allocation, enable continuous safety monitoring, and promote patient-centered care. The increasing reliance on RWE in oncology is expected to drive market growth, advance cancer research and treatment, and ultimately enhance outcomes for patients and healthcare systems alike.

To know more about why North America is leading the market growth in the Real World Evidence Solution market, get a snapshot of the Real World Evidence Solution Market Outlook https://www.delveinsight.com/report-store/real-world-evidence-solution-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Real World Evidence Solution Market Dynamics

According to the Global Cancer Observatory (2024), approximately 20 million new cancer cases were reported globally in 2022, with projections expected to reach 32.6 million by 2045. In Europe, there were an estimated 4.47 million new cases in 2022, anticipated to rise to 5.48 million by 2045. Real-world evidence (RWE) solutions are increasingly applied in oncology to inform clinical strategies and payment decisions, particularly given the diversity of patient populations and treatment approaches. By leveraging data from electronic health records (EHRs), payer claims, patient registries, and other sources, RWE provides insights into how treatments perform over time across large, varied populations. With the growing prevalence of cancer, there is an increasing demand for comprehensive data to better understand disease trends, treatment outcomes, and patient experiences. RWE solutions aggregate and analyze such real-world data to fill knowledge gaps and enhance understanding of cancer management, driving growth in this market.

Moreover, pharmaceutical and biotechnology companies are increasingly relying on RWE to support drug development and market access. Traditional randomized clinical trials (RCTs) are costly, time-intensive, and limited in scope. RWE helps identify target patient populations, refine inclusion/exclusion criteria, and optimize trial designs, leading to faster recruitment, lower costs, and higher trial success rates. For example, in August 2021, the diabetes drug Jardiance (empagliflozin) received approval for a new indication based on RWE demonstrating its effectiveness in reducing cardiovascular events in heart failure patients, including those without diabetes, complementing results from the EMPEROR-Reduced phase III trial. By offering a clearer picture of treatment effects in real-world settings, RWE ensures therapies are safe and effective across broader populations, improves patient outcomes, fosters healthcare innovation, and drives the expansion of the RWE market.

However, challenges related to RWE validation, operational implementation, and data security may pose minor constraints to market growth.

Real World Evidence Solution Market Drivers:
Increasing prevalence of chronic diseases
Growing technological advancement
Increasing application of real-world evidence solutions in pharmaceutical and biotechnology industries across the globe

Get a sneak peek at the Real World Evidence Solution market dynamics @ https://www.delveinsight.com/sample-request/real-world-evidence-solution-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Scope of the Real World Evidence Solution Market Report:
Coverage: Global
Study Period: 2022 to 2032
Key Real World Evidence Solution Companies: IQVIA Inc., Optum, Inc., Flatiron Health, Oracle, Parexel International (MA) Corporation, Aetion, Inc., Tempus, Syapse, Inc., IBM, PerkinElmer Inc., Syneos Health, TriNetX, Evidera, Clinerion, Cegedim Health Data, and others.

Which MedTech key players in the Real World Evidence Solution market are set to emerge as the trendsetter, explore @ Real World Evidence Solution Companies https://www.delveinsight.com/report-store/real-world-evidence-solution-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Trending Reports By DelveInsight:

Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market

Leber's Hereditary Optic Neuropathy Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market

Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market

Hypoplastic Left Heart Syndrome Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market

Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market

Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market

Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market

Contact Info:

Kritika Rehani
Assistant Manager, Digital Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.

Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.

This release was published on openPR.